Cipher Pharmaceuticals Inc.
CPH.TOTSXHealthcare● Active
$16.90
+$0.02(+0.12%)
Market Cap$429113332
P/E Ratio—
52W High$20.56
52W Low$11.98
Cipher Pharmaceuticals Inc.（CPH.TO）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · CPH.TO · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $27.81M | $11.54M | $20.38M | $26.64M | $7.76M |
| Depreciation & Amort. | $0.00M | $4.02M | $1.23M | $0.99M | $0.70M |
| Stock-Based Comp. | $0.00M | $1.07M | $1.19M | $0.40M | $0.14M |
| Change in Working Capital | $5.32M | $8.95M | ($3.28M) | ($3.03M) | $4.68M |
| Net Cash from Operations | $30.25M | $19.55M | $16.00M | $10.57M | $13.81M |
| Investing Activities | |||||
| Capital Expenditure | ($0.03M) | ($0.04M) | ($0.14M) | ($0.08M) | $0.00M |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($0.07M) | ($80.04M) | ($0.14M) | ($0.08M) | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | ($5.48M) | ($0.18M) | ($5.56M) | ($1.99M) | ($1.72M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($35.61M) | $39.79M | ($0.11M) | ($0.06M) | ($0.83M) |
| Net Cash from Financing | ($41.18M) | $39.30M | ($5.24M) | ($1.91M) | ($2.47M) |
| Free Cash Flow | |||||
| Free Cash Flow | $30.22M | $19.50M | $15.98M | $10.49M | $13.81M |
| FCF Margin %(computed) | 58.87% | 58.45% | 75.50% | 50.76% | 62.95% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解Cipher Pharmaceuticals Inc.
关于Cipher Pharmaceuticals Inc.（CPH.TO）现金流量表
Cipher Pharmaceuticals Inc. 2025财年经营活动现金流$0.03B，自由现金流$0.03B（FCF利润率58.87%），资本支出($0.00B)。
常见问题
CPH.TO · 4 问Cipher Pharmaceuticals Inc. 2025财年自由现金流$0.03B，同比up54.9%。
CPH.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10